BBIO Earnings

Quarterly EPS
$-0.86
Q3 2024
$-1.40
Q4 2024
$-0.88
Q1 2025
$-0.95
Q2 2025
$-0.95
Q3 2025
$-1.00
Q4 2025
$-0.84
Q1 2026
$-0.78
Q2 2026
Latest Revenue243.7M
Latest Net Income-155891000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.78243.7M-155891000+120.4%+17.9%
Q1 2026-$0.84194.5M-166555000+66.8%+4.5%
Q4 2025-$1.00154.2M-194635000+2,521.2%+28.6%
Q3 2025-$0.95120.7M-184937000+4,318.0%-10.5%
Q2 2025-$0.95110.6M-183758000+4,999.9%-143.6%
Q1 2025-$0.88116.6M-169608000-44.8%-340.0%
Q4 2024-$1.405.9M-267389000+237.1%-45.8%
Q3 2024-$0.862.7M-164254000-33.2%+20.4%
Q2 2024-$0.392.2M-75544000
Q1 2024-$0.20211.1M-36160000
Q4 2023-$0.961.7M-170328000
Q3 2023-$1.084.1M-179488000
BridgeBio Pharma (BBIO) — Earnings